Galactose Mediated Glycogen Resynthesis

January 3, 2023 updated by: University of Birmingham

Galactose Mediated Glycogen Resynthesis and the Effects on Metabolism During Subsequent Exercise

This study will compare short-term post-exercise muscle glycogen synthesis following combined galactose-glucose, glucose alone or galactose alone ingestion.

Study Overview

Detailed Description

Lactose, the sugar contained within milk, consists of glucose and galactose. Post-exercise consumption of a carbohydrate mixture containing glucose with galactose has been shown to accelerate liver glycogen repletion as compared to glucose-only provision. However, the extent to which galactose-glucose combinations influence post-exercise muscle glycogen storage has yet to be determined.

Therefore, this study will investigate whether short-term muscle glycogen storage after strenuous endurance exercise is enhanced by combined galactose-glucose or glucose only ingestion as compared to the ingestion of galactose alone.

Study Type

Interventional

Enrollment (Actual)

9

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • West Midlands
      • Birmingham, West Midlands, United Kingdom, B15 2TT
        • School of Sport, Exercise and Rehabilitation Sciences

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:.

  • Body mass index in the range: 18.5 - 27.5 kg/m2
  • Participates in endurance-based exercise (e.g. cycling, running, rowing) at least 3 times per week
  • Aerobic fitness: VO2max >45 ml/kg/min (men), >40 ml/kg/min (women)

Exclusion Criteria:

  • Lidocaine allergy
  • Current participation in another scientific/clinical study
  • Bleeding disorder/s
  • Current or recent smoker to include vaping (last 60 days)
  • Vegan
  • Existence of food intolerances
  • Poor recent health as indicated in the general health questionnaire
  • Engage in uncommon eating practices (e.g. sustained periods of fasting)
  • Diagnosed with galactosemia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Glucose alone
Participants will complete a glycogen depleting bout of exercise followed by the provision of glucose-alone over 4 hours of recovery before a subsequent bout of exercise.
Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose-alone over 4 hours of recovery before a subsequent bout of exercise.
Experimental: Galactose alone
Participants will complete a glycogen depleting bout of exercise followed by the provision of galactose-alone over 4 hours of recovery before a subsequent bout of exercise.
Young men or women will complete a glycogen depleting bout of exercise followed by the provision of galactose-alone over 4 hours of recovery before a subsequent bout of exercise.
Experimental: Glucose and galactose
Participants will complete a glycogen depleting bout of exercise followed by the provision of glucose and galactose over 4 hours of recovery before a subsequent bout of exercise.
Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose and galactose over 4 hours of recovery before a subsequent bout of exercise.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscle glycogen synthesis rates (mmol/kg/dm/h)
Time Frame: 4 hours
Muscle glycogen synthesis rates over the post-exercise recovery period
4 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Carbohydrate oxidation rates (g/min)
Time Frame: Up to 90 minutes
Total, exogenous and endogenous carbohydrate oxidation during a secondary bout of exercise
Up to 90 minutes
Fat oxidation rates (g/min)
Time Frame: Up to 90 minutes
Fat oxidation during a secondary bout of exercise
Up to 90 minutes
Plasma glucose (mmol/L)
Time Frame: Up to 6 hours
Plasma glucose during the post-exercise recovery period and during a secondary bout of exercise
Up to 6 hours
Serum insulin (mU/L)
Time Frame: Up to 6 hours
Serum insulin during the post-exercise recovery period and during a secondary bout of exercise
Up to 6 hours
Plasma galactose (mmol/L)
Time Frame: Up to 6 hours
Plasma galactose during the post-exercise recovery period and during a secondary bout of exercise
Up to 6 hours
Plasma lactate (mmol/L)
Time Frame: Up to 6 hours
Plasma lactate during the post-exercise recovery period and during a secondary bout of exercise
Up to 6 hours
Plasma non-esterified fatty acids (mmol/L)
Time Frame: Up to 6 hours
Plasma non-esterified fatty acids during the post-exercise recovery period and during a secondary bout of exercise
Up to 6 hours
Plasma glycerol (umol/L)
Time Frame: Up to 6 hours
Plasma glycerol during the post-exercise recovery period and during a secondary bout of exercise
Up to 6 hours
Plasma glucagon (pmol/L)
Time Frame: Up to 6 hours
Plasma glucagon during the post-exercise recovery period and during a secondary bout of exercise
Up to 6 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Gareth Wallis, PhD, University of Birmingham

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2019

Primary Completion (Actual)

May 1, 2020

Study Completion (Actual)

May 1, 2020

Study Registration Dates

First Submitted

March 29, 2019

First Submitted That Met QC Criteria

April 3, 2019

First Posted (Actual)

April 4, 2019

Study Record Updates

Last Update Posted (Actual)

January 4, 2023

Last Update Submitted That Met QC Criteria

January 3, 2023

Last Verified

December 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • ERN_19-0308

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe